NAP-1/IL-8 induces up-regulation of CR1 receptors in human neutrophil leukocytes.
The effect of the neutrophil-activating peptide NAP-1/IL-8 on the expression of complement receptor type 1 (CR1) in human neutrophils was studied. NAP-1/IL-8 enhanced CR1 expression at concentrations between 10(-10) and 10(-8) M. The maximum increase with respect to unstimulated control cells was on average 2.3 fold. The effect was rapid: Half-maximum enhancement was obtained in 4 min and the plateau was reached in 15 min. The chemotactic peptide fMLP, tested for comparison, was effective between 10(-9) and 10(-7) M, showed a similar time course and a somewhat higher maximum effect (2.8 fold increase). The effect of NAP-1/IL-8 was prevented by pretreatment of the cells with B.pertussis toxin and desensitization was observed following restimulation. Stimulus combination experiments suggested that NAP-1/IL-8 mobilizes the same or a similar intracellular pool of CR1 receptors as fMLP or C5a.
Division of Nephrology, Centre Médical Universitaire, Geneva, Switzerland.
J P
JP
Paccaud
J A
JA
Schifferli
M
M
Baggiolini
D002630:Chemotactic Factors / Q000494:pharmacology*; D015936:Complement C5a / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D016209:Interleukin-8; D007378:Interleukins / Q000494:pharmacology*; D007700:Kinetics; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D011951:Receptors, Complement / Q000096:biosynthesis* / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D002630:Chemotactic Factors; D016209:Interleukin-8; D007378:Interleukins; D011951:Receptors, Complement; D010566:Virulence Factors, Bordetella; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015936:Complement C5a